• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大安大略省一家儿科三级医疗保健中心产碳青霉烯酶肠杆菌科细菌携带情况的流行病学研究

Epidemiology of Carbapenemase-Producing Enterobacterales Carriage in a Paediatric Tertiary Health Care Centre of Ontario, Canada.

作者信息

Blanchard Ana C, Zahradnik Stephanie, Isabel Sandra, Mehta Kayur, Ali Mohsin, Airo Adriana, Streitenberger Laurie, Freeman Renee, Yau Yvonne Cw, Campigotto Aaron, Tadros Manal, Science Michelle

机构信息

Division of Infectious Diseases, Department of Paediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.

Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Assoc Med Microbiol Infect Dis Can. 2024 Jul 19;9(2):104-107. doi: 10.3138/jammi-2023-0037. eCollection 2024 Jun.

DOI:10.3138/jammi-2023-0037
PMID:40641812
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12169428/
Abstract

INTRODUCTION

The epidemiology of carbapenemase-producing Enterobacterales (CPE) in hospitalized children in low endemicity settings is not well known. We aim to describe it in a large tertiary paediatric health care centre in Canada.

METHODS

A repeated point-prevalence study including all inpatients was conducted at the Hospital for Sick Children, Toronto, for surveillance purposes over 3 days serially in April 2017, April 2019, and April 2022. Patients in the emergency department and medical day units were excluded. Stools or rectal swabs were analyzed for CPE identification, with confirmatory testing at the provincial reference laboratory.

RESULTS

We detected CPE colonization in 0.4% (1/242), 0.7% (2/278), and 0.9% (2/220) of inpatients in 2017, 2019, and 2022, respectively. Identified CPE included OXA-48-like and NDM beta-lactamases in and . All patients with CPE colonization had a history of travel or hospitalization outside of Canada, including in the Middle East and Asia.

DISCUSSION

CPE colonization in children hospitalized in this Canadian hospital was detected. A history of prolonged travel or hospitalization outside of Canada are risk factors that should be considered in targeted screening programs.

摘要

引言

在低流行地区的住院儿童中,产碳青霉烯酶肠杆菌科细菌(CPE)的流行病学情况尚不清楚。我们旨在描述加拿大一家大型三级儿科医疗中心的相关情况。

方法

2017年4月、2019年4月和2022年4月,在多伦多病童医院连续3天进行了一项重复的点患病率研究,纳入所有住院患者以进行监测。急诊科和医疗日间病房的患者被排除。对粪便或直肠拭子进行分析以鉴定CPE,并在省级参考实验室进行确证检测。

结果

2017年、2019年和2022年住院患者中CPE定植的检出率分别为0.4%(1/242)、0.7%(2/278)和0.9%(2/220)。鉴定出的CPE包括[具体年份1]中的OXA - 48样和NDMβ - 内酰胺酶以及[具体年份]中的[具体酶型]。所有CPE定植患者都有在加拿大境外旅行或住院的历史,包括中东和亚洲。

讨论

在这家加拿大医院住院的儿童中检测到了CPE定植。在针对性筛查项目中应考虑在加拿大境外长时间旅行或住院的历史作为风险因素。

相似文献

1
Epidemiology of Carbapenemase-Producing Enterobacterales Carriage in a Paediatric Tertiary Health Care Centre of Ontario, Canada.加拿大安大略省一家儿科三级医疗保健中心产碳青霉烯酶肠杆菌科细菌携带情况的流行病学研究
J Assoc Med Microbiol Infect Dis Can. 2024 Jul 19;9(2):104-107. doi: 10.3138/jammi-2023-0037. eCollection 2024 Jun.
2
Who should be screened for carbapenemase-producing Enterobacterales and when? A systematic review.应该对哪些人进行产碳青霉烯酶肠杆菌科的筛查,以及何时进行筛查?系统评价。
J Hosp Infect. 2023 Dec;142:74-87. doi: 10.1016/j.jhin.2023.09.018. Epub 2023 Oct 5.
3
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
4
[Epidemiological characteristics of patients with carbapenemase-producing NDM Enterobacterales isolates in a high-complexity hospital].[一家高复杂性医院中产碳青霉烯酶NDM肠杆菌科细菌分离株患者的流行病学特征]
Rev Esp Quimioter. 2025 Jun 4;38(4):287-293. doi: 10.37201/req/015.2025.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Examining the impact and response to an outbreak of carbapenemase-producing in a neonatal unit in the United Kingdom: An outbreak report.调查英国一家新生儿病房产碳青霉烯酶疫情的影响及应对情况:疫情报告
J Infect Prev. 2024 Jul;25(4):142-149. doi: 10.1177/17571774241239222. Epub 2024 Mar 14.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR).阿根廷成人重症监护病房多重耐药感染的患病率及死亡率(PREV-AR)。
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0142624. doi: 10.1128/aac.01426-24. Epub 2025 Jan 22.
9
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.非 ICU 住院患者预防谵妄的非药物干预措施。
Cochrane Database Syst Rev. 2021 Nov 26;11(11):CD013307. doi: 10.1002/14651858.CD013307.pub3.
10
Interventions for preventing and reducing the use of physical restraints of older people in general hospital settings.预防和减少一般医院环境中老年人身体约束使用的干预措施。
Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD012476. doi: 10.1002/14651858.CD012476.pub2.

本文引用的文献

1
Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2016-2020.2016 - 2020年加拿大急症护理医院的医疗保健相关感染及抗菌药物耐药性
Can Commun Dis Rep. 2022 Jul 7;48(7-8):308-324. doi: 10.14745/ccdr.v48i78a03.
2
Modelling interventions and contact networks to reduce the spread of carbapenem-resistant organisms between individuals in the ICU.建立模型干预和接触网络,以减少 ICU 中个体之间耐碳青霉烯类抗生素的细菌的传播。
J Hosp Infect. 2023 Jun;136:1-7. doi: 10.1016/j.jhin.2023.02.016. Epub 2023 Mar 11.
3
Audit and feedback as a tool to increase compliance with carbapenemase-producing Enterobacteriaceae (CPE) screening and decrease CPE transmission in the hospital.审核和反馈作为一种工具,以提高耐碳青霉烯肠杆菌科(CPE)筛查的合规性,并降低医院内 CPE 的传播。
Infect Control Hosp Epidemiol. 2023 Nov;44(11):1788-1792. doi: 10.1017/ice.2022.224. Epub 2022 Sep 9.
4
Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children.西班牙儿童耐碳青霉烯或产碳青霉烯酶肠杆菌科血流感染的死亡率预测因子和临床特征。
J Antimicrob Chemother. 2021 Jan 1;76(1):220-225. doi: 10.1093/jac/dkaa397.
5
Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital.某大学医院 ICU 和 HSCT 病房高危患者中产碳青霉烯酶肠杆菌科直肠定植的流行病学和危险因素。
Antimicrob Resist Infect Control. 2020 Sep 23;9(1):155. doi: 10.1186/s13756-020-00816-4.
6
Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients.医院住院患者中产碳青霉烯酶肠杆菌科细菌普遍筛查的成本效益分析
Eur J Clin Microbiol Infect Dis. 2017 Jun;36(6):1047-1055. doi: 10.1007/s10096-016-2890-7. Epub 2017 Jan 11.
7
Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?产 blaKPC 碳青霉烯类耐药肠杆菌科无症状直肠携带:哪些人易发生临床感染?
Clin Microbiol Infect. 2013 May;19(5):451-6. doi: 10.1111/j.1469-0691.2012.03888.x. Epub 2012 May 7.
8
Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.急性医疗机构中耐碳青霉烯类或产碳青霉烯酶肠杆菌科细菌感染的控制指南。
MMWR Morb Mortal Wkly Rep. 2009 Mar 20;58(10):256-60.